BACKGROUND: There is limited evidence that Merkel cell carcinoma (MCC) arising from a nodal basin without evidence of a primary cutaneous (PC) site has better prognosis. We present our experience at 2 tertiary care referral centers with stage III MCC with and without a PC site. METHODS: Fifty stage III MCC patients were identified between 1996 and 2011. Clinical data were analyzed, with primary endpoints being disease-free survival and overall survival. RESULTS: Of stage III patients, 34 patients presented with a PC site and 16 patients with an unknown primary (UP) site. Treatment strategies varied; of patients with UP vs. PC sites, 25% vs. 44% underwent combined regional lymphadenectomy and radiation, with an additional 25% vs. 15% receiving chemotherapy. The median disease-free survival for a UP site was not reached vs. 15 months for a PC site (hazards ratio = .48, P = .18). The median overall survival for a UP site was not reached vs 21 months for a PC site (hazards ratio = .34, P = .03). Multivariate analysis showed that UP status was a significant factor in overall survival (P = .002). CONCLUSIONS: Stage III MCC with a UP site portends a better prognosis than MCC with a PC site.
BACKGROUND: There is limited evidence that Merkel cell carcinoma (MCC) arising from a nodal basin without evidence of a primary cutaneous (PC) site has better prognosis. We present our experience at 2 tertiary care referral centers with stage III MCC with and without a PC site. METHODS: Fifty stage III MCC patients were identified between 1996 and 2011. Clinical data were analyzed, with primary endpoints being disease-free survival and overall survival. RESULTS: Of stage III patients, 34 patients presented with a PC site and 16 patients with an unknown primary (UP) site. Treatment strategies varied; of patients with UP vs. PC sites, 25% vs. 44% underwent combined regional lymphadenectomy and radiation, with an additional 25% vs. 15% receiving chemotherapy. The median disease-free survival for a UP site was not reached vs. 15 months for a PC site (hazards ratio = .48, P = .18). The median overall survival for a UP site was not reached vs 21 months for a PC site (hazards ratio = .34, P = .03). Multivariate analysis showed that UP status was a significant factor in overall survival (P = .002). CONCLUSIONS: Stage III MCC with a UP site portends a better prognosis than MCC with a PC site.
Authors: Dirk Schadendorf; Paul Nghiem; Shailender Bhatia; Axel Hauschild; Philippe Saiag; Lisa Mahnke; Subramanian Hariharan; Howard L Kaufman Journal: Oncoimmunology Date: 2017-08-31 Impact factor: 8.110
Authors: Jürgen C Becker; Andreas Stang; James A DeCaprio; Lorenzo Cerroni; Celeste Lebbé; Michael Veness; Paul Nghiem Journal: Nat Rev Dis Primers Date: 2017-10-26 Impact factor: 52.329
Authors: Natalie Vandeven; Christopher W Lewis; Vladimir Makarov; Nadeem Riaz; Kelly G Paulson; Daniel Hippe; Amy Bestick; Ryan Doumani; Tessa Marx; Seesha Takagishi; Timothy A Chan; Jaehyuk Choi; Paul Nghiem Journal: Clin Cancer Res Date: 2017-12-15 Impact factor: 12.531
Authors: Kelly L Harms; Mark A Healy; Paul Nghiem; Arthur J Sober; Timothy M Johnson; Christopher K Bichakjian; Sandra L Wong Journal: Ann Surg Oncol Date: 2016-05-19 Impact factor: 5.344